Merck & CompanyvsPacira BioSciences

MRK and PCRX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$132.81

Value $328B

-3.61%
MRK's page

Merck & Company (MRK) has a market value of $328B and Pacira BioSciences (PCRX) $1.5B. The P/E is 133.9 for MRK and 39.2 for PCRX. Dividend yield: MRK 2.56%, PCRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$328B

    PCRX$1.5B

    MRK is 222 times PCRX

  • Revenue, 12 months

    MRK$67.4B

    PCRX$743M

    MRK is 91 times PCRX

  • Net income, 12 months

    MRK$2.5B

    PCRX$38M

    MRK is 65 times PCRX

  • Operating margin

    MRK–

    PCRX4.8%

  • ROIC

    MRK3.9%

    PCRX2.4%

    1.5 points apart

  • P/E

    MRK133.9

    PCRX39.2

    MRK is 3.4 times PCRX

  • Dividend yield

    MRK2.6%

    PCRX0.0%

    2.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

Prices are not available right now.

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyPCRXPacira BioSciences

Valuation

MRKPCRX
Valuation
Price$132.81$36.48
Market value$328B$1.5B
Enterprise value (EV)$372B$1.5B
P/E133.939.2
P/E, 5-year median14.8–
P/B7.32.1
EV/EBIT78.241.2
Free cash flow yield4.5%11.4%

Results and growth

MRKPCRX
Results and growth
Revenue, 12 months$67.4B$743M
Net income, 12 months$2.5B$38M
Free cash flow, 12 months$14.7B$169M
Earnings per share, 12 months$0.98$0.93
Revenue growth, year on year1.3%3.6%
Revenue growth a year, past+9.4%over 5 years+11.1%over 5 years
EPS growth a year, past+21.2%over 5 years-45.5%over 5 years

Margins and returns on capital

MRKPCRX
Margins and returns on capital
Gross margin71.8%78.7%
Operating margin–4.8%
Net margin3.6%5.1%
ROIC3.9%2.4%
ROE5.2%5.5%

Balance sheet

MRKPCRX
Balance sheet
Cash$9.7B$296M
Total debt$53.8B$340M
Net debt / EBITDA5.7-0.0
Interest cover2.4×2.5×

Dividends and buybacks

MRKPCRX
Dividends and buybacks
Dividend yield2.6%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.6%10.0%
Shareholder yield4.1%10.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or PCRX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Pacira BioSciences?

By market value, Merck & Company ($328B) is about 222.3 times Pacira BioSciences ($1.5B), at today's prices.

Which pays the higher dividend, MRK or PCRX?

The dividend yield at today's price is 2.56% for Merck & Company and none for Pacira BioSciences. Over the last twelve months they paid $3.40 and – per share.

What is the P/E of MRK and PCRX?

At today's price, the P/E is 133.9 for MRK and 39.2 for PCRX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Merck & Company or Pacira BioSciences?

Over the last twelve months, the net margin was 3.6% for Merck & Company and 5.1% for Pacira BioSciences, and the operating margin – and 4.8%. Revenue was $67.4B and $743M.

Which is the better investment, Merck & Company or Pacira BioSciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.